1,173 research outputs found
Colony-specific differences in decadal longitudinal body composition of a capital-breeding marine top predator
he long‐term studies included in this paper were funded by the Natural Environment Research Council through the grant ‘SMRU Long‐term measurement of marine mammal population structure, dynamics and trophic interactions’, grant reference SMRU1001. PP was in receipt of NERC grant no. NE/G008930/1 and Esmée Fairbairn Foundation funding during the work. SCS was supported as a postdoctoral fellow in an EPSRC award to RK and PP.1. Capital breeding animals such as true seals (Phocidae) rely on accumulated body reserves to rear offspring. A mother's body composition at the start of a breeding episode may depend on recent environmental conditions and sets the resources available for the reproductive episode. 2. At two grey seal (Halichoerus grypus) breeding colonies with contrasting demographic characteristics, factors influencing individual variation and temporal trends in the body composition (expressed as the lipid‐to‐protein mass ratio) of females were examined. 3. Maternal reproductive expenditure, and the consequences for mothers and their pups, were investigated. 4. Individual variation in postpartum maternal body composition was considerable. Mean values of 27% (±5%) lipid and 18% (±1%) protein were estimated by hydrogen isotope dilution. No evidence of age effects was detected. 5. Mothers with a high lipid‐to‐protein mass ratio expended a higher proportion of lipid resources, conserved protein and returned with more protein the following year. 6. Average maternal postpartum body composition was similar between the two colonies, but temporal patterns differed at one colony where pup production was decreasing from another where pup production was increasing. Mothers at the declining colony consistently weaned larger pups than mothers at the increasing colony across the range of mother sizes, but measures of maternal body composition did not predict pup weaning masses.PostprintPeer reviewe
The vegetation map of France going numerical: a new harmonised national geographical database
5 pagesIn this paper we present the digitalisation of the map of the vegetation of France edited in 64 sheets by the CNRS between 1947 and 1991. The geographical covers and the databases built during this work are gathered in a geographical database called "Base de Données Géographique de la VÉGétation de la France" (BDGveg_FR). The main covers show respectively the vegetation succession stages, as a georeferenced scan, at 1/200,000, and the harmonised map of the potential vegetation, in a vector format, at 1/1,000,000. The harmonised map of the potential vegetation is linked with a national 6-level typology synthesised from the keys of the 64 sheets. The BDGveg_FR is unique because of its period of time, its local and national scales, its exhaustive cover, and its information on the plant associations. Thus, it is actually complementary to the other databases on the French vegetation presently available. It is particularly well appropriate to assess the impact of global changes (e.g. climate, atmospheric pollution) on ecosystem behaviour
A cellular model to study drug-induced liver injury in nonalcoholic fatty liver disease: application to acetaminophen
International audienceObesity and nonalcoholic fatty liver disease (NAFLD) can increase susceptibility to hepatotoxicity induced by some xenobiotics including drugs, but the involved mechanisms are poorly understood. For acetaminophen (APAP), a role of hepatic cytochrome P450 2E1 (CYP2E1) is suspected since the activity of this enzyme is consistently enhanced during NAFLD. The first aim of our study was to set up a cellular model of NAFLD characterized not only by triglyceride accumulation but also by higher CYP2E1 activity. To this end, human HepaRG cells were incubated for one week with stearic acid or oleic acid, in the presence of different concentrations of insulin. Although cellular triglycerides and the expression of lipid-responsive genes were similar with both fatty acids, CYP2E1 activity was significantly increased only by stearic acid. CYP2E1 activity was reduced by insulin and this effect was reproduced in cultured primary human hepatocytes. Next, APAP cytotoxicity was assessed in HepaRG cells with or without lipid accretion and CYP2E1 induction. Experiments with a large range of APAP concentrations showed that the loss of ATP and glutathione was almost always greater in the presence of stearic acid. In cells pretreated with the CYP2E1 inhibitor chlormethiazole, recovery of ATP was significantly higher in the presence of stearate with low (2.5 mM) or high (20 mM) concentrations of APAP. Levels of APAP-glucuronide were significantly enhanced by insulin. Hence, HepaRG cells can be used as a valuable model of NAFLD to unveil important metabolic and hormonal factors which can increase susceptibility to drug-induced hepatotoxicit
Global Characterisation of Coagulopathy in Isolated Traumatic Brain Injury (iTBI): A CENTER-TBI Analysis.
BACKGROUND: Trauma-induced coagulopathy in patients with traumatic brain injury (TBI) is associated with high rates of complications, unfavourable outcomes and mortality. The mechanism of the development of TBI-associated coagulopathy is poorly understood. METHODS: This analysis, embedded in the prospective, multi-centred, observational Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) study, aimed to characterise the coagulopathy of TBI. Emphasis was placed on the acute phase following TBI, primary on subgroups of patients with abnormal coagulation profile within 4 h of admission, and the impact of pre-injury anticoagulant and/or antiplatelet therapy. In order to minimise confounding factors, patients with isolated TBI (iTBI) (n = 598) were selected for this analysis. RESULTS: Haemostatic disorders were observed in approximately 20% of iTBI patients. In a subgroup analysis, patients with pre-injury anticoagulant and/or antiplatelet therapy had a twice exacerbated coagulation profile as likely as those without premedication. This was in turn associated with increased rates of mortality and unfavourable outcome post-injury. A multivariate analysis of iTBI patients without pre-injury anticoagulant therapy identified several independent risk factors for coagulopathy which were present at hospital admission. Glasgow Coma Scale (GCS) less than or equal to 8, base excess (BE) less than or equal to - 6, hypothermia and hypotension increased risk significantly. CONCLUSION: Consideration of these factors enables early prediction and risk stratification of acute coagulopathy after TBI, thus guiding clinical management
Prevalence and Relevance of Vitamin D Deficiency in Newly Diagnosed Breast Cancer Patients : A Pilot Study
(1) Background: Vitamin D plays an important role in many types of cancer. It was the aim
of this study to analyze serum 25-hydroxyvitamin D (25(OH)D) levels in newly diagnosed breast
cancer patients, and the association with prognostic and lifestyle factors. (2) Methods: 110 nonmetastatic breast cancer patients were included in the prospective observational “BEGYN” study at
Saarland University Medical Center between September 2019 and January 2021. At the initiation
visit, serum 25(OH)D levels were measured. Clinicopathological data on prognosis, nutrition, and
lifestyle were extracted from data files and obtained using a questionnaire. (3) Results: Median
serum 25(OH)D in breast cancer patients was 24 ng/mL (range 5–65 ng/mL), with 64.8% of patients
being vitamin D deficient. 25(OH)D was higher among patients that reported the use of vitamin D
supplements (43 ng/mL versus 22 ng/mL; p < 0.001), and in summer compared to other seasons
(p = 0.03). Patients with moderate vitamin D deficiency were less likely to have triple negative breast
cancer (p = 0.047). (4) Conclusions: Routinely measured vitamin D deficiency is common in breast
cancer patients and needs to be detected and treated. However, our results do not support the
hypothesis that vitamin D deficiency may be a main prognostic factor for breast cancer
Outcomes of COVID-19 related hospitalization among people with HIV in the ISARIC WHO Clinical Characterization Protocol (UK):a prospective observational study
BACKGROUND:Evidence is conflicting about how HIV modulates COVID-19. We compared the presentation characteristics and outcomes of adults with and without HIV who were hospitalized with COVID-19 at 207 centers across the United Kingdom and whose data were prospectively captured by the ISARIC WHO CCP study. METHODS:We used Kaplan-Meier methods and Cox regression to describe the association between HIV status and day-28 mortality, after separate adjustment for sex, ethnicity, age, hospital acquisition of COVID-19 (definite hospital acquisition excluded), presentation date, ten individual comorbidities, and disease severity at presentation (as defined by hypoxia or oxygen therapy). RESULTS:Among 47,592 patients, 122 (0.26%) had confirmed HIV infection and 112/122 (91.8%) had a record of antiretroviral therapy. At presentation, HIV-positive people were younger (median 56 versus 74 years; p<0.001) and had fewer comorbidities, more systemic symptoms and higher lymphocyte counts and C-reactive protein levels. The cumulative day-28 mortality was similar in the HIV-positive vs. HIV-negative groups (26.7% vs. 32.1%; p=0.16), but in those under 60 years of age HIV-positive status was associated with increased mortality (21.3% vs. 9.6%; p<0.001 [log-rank test]). Mortality was higher among people with HIV after adjusting for age (adjusted hazard ratio [aHR] 1.47, 95% confidence interval [CI] 1.01-2.14; p=0.05), and the association persisted after adjusting for the other variables (aHR 1.69; 95% CI 1.15-2.48; p=0.008) and when restricting the analysis to people aged <60 years (aHR 2.87; 95% CI 1.70-4.84; p<0.001). CONCLUSIONS:HIV-positive status was associated with an increased risk of day-28 mortality among patients hospitalized for COVID-19
The utility of routine surveillance screening with magnetic resonance imaging (MRI) to detect tumour recurrence in children with low-grade central nervous system (CNS) tumours : a systematic review
Background: Magnetic resonance imaging (MRI) is routinely used as a surveillance tool to detect early asymptomatic tumour recurrence with a view to improving patient outcomes. This systematic review aimed to assess its utility in children with low-grade CNS tumours. Methods: Using standard systematic review methods, twelve databases were searched up to January 2017. Results: Seven retrospective case series studies (n = 370 patients) were included, with average follow-up ranging from 5.6 to 7 years. No randomised controlled trials (RCTs) were identified. Due to study heterogeneity only a descriptive synthesis could be undertaken. Imaging was most frequent in the first year post-surgery (with 2–4 scans) reducing to around half this frequency in year two and annually thereafter for the duration of follow-up. Diagnostic yield ranged from 0.25 to 2%. Recurrence rates ranged from 5 to 41%, with most recurrences asymptomatic (range 65–100%). Collectively, 56% of recurrences had occurred within the first year post-treatment (46% in the first 6-months), 68% by year two and 90% by year five. Following recurrence, 90% of patients underwent treatment changes, mainly repeat surgery (72%). Five-year OS ranged from 96 to 100%, while five-year recurrence-free survival ranged from 67 to 100%. None of the studies reported quality of life measures. Conclusion: This systematic review highlights the paucity of evidence currently available to assess the utility of MRI surveillance despite it being routine clinical practice and costly to patients, their families and healthcare systems. This needs to be evaluated within the context of an RCT
Living ethics: a stance and its implications in health ethics
Moral or ethical questions are vital because they affect our daily lives: what is the best choice we can make, the best action to take in a given situation, and ultimately, the best way to live our lives? Health ethics has contributed to moving ethics toward a more experience-based and user-oriented theoretical and methodological stance but remains in our practice an incomplete lever for human development and flourishing. This context led us to envision and develop the stance of a “living ethics”, described in this inaugural collective and programmatic paper as an effort to consolidate creative collaboration between a wide array of stakeholders. We engaged in a participatory discussion and collective writing process known as instrumentalist concept analysis. This process included initial local consultations, an exploratory literature review, the constitution of a working group of 21 co-authors, and 8 workshops supporting a collaborative thinking and writing process. First, a living ethics designates a stance attentive to human experience and the role played by morality in human existence. Second, a living ethics represents an ongoing effort to interrogate and scrutinize our moral experiences to facilitate adaptation of people and contexts. It promotes the active and inclusive engagement of both individuals and communities in envisioning and enacting scenarios which correspond to their flourishing as authentic ethical agents. Living ethics encourages meaningful participation of stakeholders because moral questions touch deeply upon who we are and who we want to be. We explain various aspects of a living ethics stance, including its theoretical, methodological, and practical implications as well as some barriers to its enactment based on the reflections resulting from the collaborative thinking and writing process
The role of high-dose myeloablative chemotherapy with haematopoietic stem cell transplantation (HSCT) in children with central nervous system (CNS) tumours:protocol for a systematic review and meta-analysis
OBJECTIVES: The objective of the study is to conduct a systematic review to compare the effects of high-dose chemotherapy (HDCT) with autologous haematopoietic stem cell transplantation (HSCT) versus standard-dose chemotherapy (SDCT) in children with malignant central nervous system (CNS) tumours. METHODS: Standard systematic review methods aimed at minimising bias will be employed for study identification, selection and data extraction. Ten electronic databases will be searched, along with citation searching and reference checking. Studies assessing the effects of HDCT with HSCT in children with CNS tumours will be included. The outcomes are survival (overall, progression-free, event-free, disease-free), response rates, short- and long-term adverse events and health-related quality of life (HRQoL). Two reviewers will independently screen and select randomised and non-randomised controlled trials and controlled and uncontrolled observational studies for inclusion. Quality assessment will be tailored to the different study designs. Where possible data will be summarised using combined estimates of effect for the hazard ratio for survival outcomes and the risk ratio for response rates. A fixed effect model will be used; sub-group analyses and meta-regression will be used to explore potential sources of heterogeneity between studies. DISCUSSION: Given the poor prognosis of malignant brain tumours in children in terms of survival and quality of life, this review will help guide clinical practice by summarising the current evidence on the use of high-dose myeloblative chemotherapy with stem cell support in children with CNS tumours
Adjusting Early Warning Score by clinical assessment:A study protocol for a Danish cluster-randomised, multicentre study of an Individual Early Warning Score (I-EWS)
- …